Antibodies to the N-Terminal Domain of Angiotensin-Converting Enzyme (ACE2) That Block Its Interaction with SARS-CoV-2 S Protein.
Dokl Biochem Biophys
; 502(1): 1-4, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1555645
ABSTRACT
SARS-CoV-2 is a new coronavirus that is the cause of COVID-19 pandemic. To enter the cell, the virus interacts via its surface S protein with angiotensin-converting enzyme 2 (ACE2), the main entry receptor on the cell membrane. Most of protective antibodies, including those induced by vaccinations, target the S protein, preventing its interaction with the ACE2 receptor. We have evaluated an alternative strategy for blocking the S-ACE2 interaction using new antipeptide antibodies to the N-terminus of the ACE2 molecule. These antibodies allow detection of human ACE2 in vitro and ex vivo.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pandemics
/
Angiotensin-Converting Enzyme 2
/
COVID-19
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Dokl Biochem Biophys
Journal subject:
Biophysics
/
Biochemistry
Year:
2022
Document Type:
Article
Affiliation country:
S160767292201001X
Similar
MEDLINE
...
LILACS
LIS